短程应用rhG-CSF佐治小儿急性白血病疗效观察

摘要:

目的 探讨短程应用重组人粒细胞集落刺激因子（ｒｈＧ－ ＣＳＦ） 佐治急性白血病强化疗所致骨髓抑制期的疗效。方法 将４５ 例急性白血病随机分为两组。对照组予常规治疗，治疗组在常规治疗同时加用ｒｈＧ－ ＣＳＦ，短程应用，共计３ ｄ。结果 治疗组骨髓抑制期恢复时间（７．７ ±１ ．２２ ｄ） ，较对照组（１０ ．７ ±４ ．５６ ｄ） 显著缩短（ Ｐ＜ ０．０５），继发感染发生率（６０ ．８ ％）与对照组（６６ ．７ ％） 相比差异无显著意义（Ｐ＞０ ．０５），但感染控制时间治疗组（４．３７ ±５ ．６１ ｄ） 较对照组（７ ．０８ ±３．６１ ｄ） 明显缩短（Ｐ＜０ ．０５），成分输血量（ 均值３４０ ｍｌ） 较对照组（均值５４０ ｍｌ）显著减少（ Ｐ＜０ ．０１），缓解率及缓解后无病生存期无明显差异（Ｐ＞ ０．０５）。结论 ｒｈＧ－ ＣＳＦ短程应用佐治急性白血病对强化疗后缓解骨髓抑制，顺利完成强化疗方案，疗效肯定，费用亦降低，值得临床推广应用。

Abstract:

Objective To evaluate the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in the short-course supplementary treatment of acute leukemia on the inhibitory period of bone marrow induced by intense chemotherapy. Methods Forty-five cases of acute leukemia were divided randomly into two groups.Routine treatment was conducted in the routine group , while the patients in the supplementary therapy group received rhG-CSF on the first three days as a supplementary therapy besides routine treatment. Results The inhibitory period of bone marrow and controlled period of infection were significantly shortened in the supplementary therapy group than in the routine group. The required volume of blood transfusion was significantly smaller in the supplementary therapy group (340 ml) than in Group R (540 ml). There was no significant difference between the two groups in the secondary infection occurrence rate, remission rate, and disease-free survival. Conclusions The short-course administration of rhG-CSF as a supplementary therapy seems to reduce the inhibition of bone marrow induced by intense chemotherapy in acute leukemia and thus may be helpful to accomplish the intense chemotherapy. Due to the beneficial effects and low costs of rhG-CSF, it may be worthwhile to popularize its application as a supplementary therapy in acute leukemia.